
Telmisartan (40mg) + Metoprolol Succinate (25mg)
Active composition
+1 more active ingredient
Telmisartan selectively blocks angiotensin II receptors, leading to vasodilation and decreased blood pressure.
Metoprolol Succinate blocks beta-1 adrenergic receptors, leading to decreased heart rate and contractility, thereby lowering blood pressure.
Medical applications
Metocure-T 25 Tablet ER is a combination antihypertensive medication containing Telmisartan 40 mg and Metoprolol Succinate 25 mg, formulated for extended release. Telmisartan, an angiotensin II receptor blocker (ARB), selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, which leads to decreased blood pressure. Metoprolol Succinate, a cardioselective beta-1 adrenergic receptor blocker, reduces heart rate, myocardial contractility, and cardiac output, contributing to its antihypertensive effect. The extended-release formulation ensures a sustained therapeutic effect, improving patient compliance by allowing once-daily dosing. Metocure-T 25 is indicated for the management of essential hypertension, providing effective blood pressure control and reducing the risk of cardiovascular events such as stroke and myocardial infarction. It may also be beneficial in patients with concomitant conditions like ischemic heart disease or heart failure, where beta-blockade is advantageous. Caution is advised in patients with bradycardia, severe hepatic or renal impairment, and asthma or other bronchospastic conditions. Common adverse effects include dizziness, fatigue, and hypotension. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy to ensure safety and efficacy.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Metocure-T 25 Tablet ER is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Metocure-T 25 Tablet ER is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
Medical Advice
Metocure-T 25 Tablet ER is safe to use in patients with kidney disease. No dose adjustment of Metocure-T 25 Tablet ER is recommended.
Exercise Caution
Metocure-T 25 Tablet ER may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Metocure-T 25 Tablet ER should be used with caution in patients with liver disease. Dose adjustment of Metocure-T 25 Tablet ER may be needed. Please consult your doctor.
Regular Checkup
0 reviews for Metocure-T 25 Tablet ER

Telmisartan (40mg) + Metoprolol Succinate (25mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Telmisartan selectively blocks angiotensin II receptors, leading to vasodilation and decreased blood pressure.
Metoprolol Succinate blocks beta-1 adrenergic receptors, leading to decreased heart rate and contractility, thereby lowering blood pressure.
Medical applications
Metocure-T 25 Tablet ER is a combination antihypertensive medication containing Telmisartan 40 mg and Metoprolol Succinate 25 mg, formulated for extended release. Telmisartan, an angiotensin II receptor blocker (ARB), selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, which leads to decreased blood pressure. Metoprolol Succinate, a cardioselective beta-1 adrenergic receptor blocker, reduces heart rate, myocardial contractility, and cardiac output, contributing to its antihypertensive effect. The extended-release formulation ensures a sustained therapeutic effect, improving patient compliance by allowing once-daily dosing. Metocure-T 25 is indicated for the management of essential hypertension, providing effective blood pressure control and reducing the risk of cardiovascular events such as stroke and myocardial infarction. It may also be beneficial in patients with concomitant conditions like ischemic heart disease or heart failure, where beta-blockade is advantageous. Caution is advised in patients with bradycardia, severe hepatic or renal impairment, and asthma or other bronchospastic conditions. Common adverse effects include dizziness, fatigue, and hypotension. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy to ensure safety and efficacy.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Metocure-T 25 Tablet ER is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Metocure-T 25 Tablet ER is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
Medical Advice
Metocure-T 25 Tablet ER is safe to use in patients with kidney disease. No dose adjustment of Metocure-T 25 Tablet ER is recommended.
Exercise Caution
Metocure-T 25 Tablet ER may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Metocure-T 25 Tablet ER should be used with caution in patients with liver disease. Dose adjustment of Metocure-T 25 Tablet ER may be needed. Please consult your doctor.
Regular Checkup
0 reviews for Metocure-T 25 Tablet ER















